Vertex Pharmaceuticals Investor Presentation — August 2024

Document content

©2024 Vertex Pharmaceuticals IncorporatedAGENDA

Susie Lisa, CFA, Senior Vice President, Investor Relations

CEO Perspective and Pipeline Update

Reshma Kewalramani, M.D., Chief Executive Officer and President

Stuart Arbuckle, Executive Vice President and Chief Operating Officer

Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer

©2024 Vertex Pharmaceuticals Incorporated 2SAFE HARBOR STATEMENT & NON-GAAP FINANCIAL MEASURES

3This presentation contains forward -looking statements that are subject to risks, uncertainties and other factors . All statements other than statements of historical fact are statements that could be deemed forward -looking

statements, including all statements regarding the intent, belief, or current expectation of Vertex and members of the Vertex senior management team. Forward -looking statements are not purely historical and may be

accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning . Such statements include, without

limitation, the information provided regarding and expectations for future financial and operating performance, the section captioned “Raising Full Year 2024 Produce Revenue Guidance,” and statements regarding (i)

expectations, development plans and timelines for the company’s products and pipeline programs, including expectations for anticipated near -term commercial launch opportunities, anticipated benefits of new products and

relevant patient populations, and plans to broaden, diversify and rapidly advance our R&D pipeline across modalities, (ii) expectations for the vanzacaftor triple, including with respect to the preparations for commercial

launch in multiple geographies and a substantially lower royalty burden, (iii) expectations regarding VX-522 to reach the >5,000 CF patients who cannot benefit from a CFTR modulator, VX-522 study progress and plans to have

VX-522 data in the first half of 2025 , (iv) expectations for our acute pain program, including beliefs regarding the potential benefits of suzetrigine as a non-opioid treatment option and that suzetrigine holds the potential to

reshape the treatment of acute pain in the U.S., plans to seek a broad acute pain label, expectations regarding the target profile and treatment settings for suzetrigine ,updates on the clinical statuses of the intravenous and

oral formulations of VX-993, our expectations and plans for near -term launch and beliefs regarding the commercial potential of suzetrigine , including as multi -billion dollar opportunity, our estimates on the treatable patient